Recombinant fusion protein of IL3 and Lidamycin, preparation method and application thereof

The invention relates to a strengthened fusion protein of an anticancer drug lidamycin, i.e. mIL3-LDM from mutated I131L and F132L, and a coding gene thereof. The invention also relates to a genetic engineering construction method of the fusion protein and application of the strengthened fusion prot...

Full description

Saved in:
Bibliographic Details
Main Authors LI SHUANGJING, JIANG LINLIN, YAN CIHUI, LIN YANG, MIAO QINGFANG, LIU RONG, LI ZHENZHEN, HU YUNHUI, PENG HONGWEI, ZHANG YANJUN, SHAO RONGGUANG, ZHANG XIULI, YANG CHUNZHENG, XIONG DONGSHENG, ZHEN YONGSU
Format Patent
LanguageChinese
English
Published 15.05.2013
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:The invention relates to a strengthened fusion protein of an anticancer drug lidamycin, i.e. mIL3-LDM from mutated I131L and F132L, and a coding gene thereof. The invention also relates to a genetic engineering construction method of the fusion protein and application of the strengthened fusion protein.
Bibliography:Application Number: CN20111139158